247 related articles for article (PubMed ID: 34549914)
1. Minimal Residual Disease in Multiple Myeloma: Ready for Prime Time?
Mina R; Bonello F; Oliva S
Cancer J; 2021 May-Jun 01; 27(3):247-255. PubMed ID: 34549914
[TBL] [Abstract][Full Text] [Related]
2. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
3. Measurable residual disease in multiple myeloma and light chain amyloidosis: more than meets the eye.
Vaxman I; Gertz MA
Leuk Lymphoma; 2021 Jul; 62(7):1544-1553. PubMed ID: 33508994
[TBL] [Abstract][Full Text] [Related]
4. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].
Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022
[No Abstract] [Full Text] [Related]
5. Measurable Residual Disease and Decision-Making in Multiple Myeloma.
Derman BA; Fonseca R
Hematol Oncol Clin North Am; 2024 Apr; 38(2):477-495. PubMed ID: 38184470
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
7. What to do with minimal residual disease testing in myeloma.
Manasanch EE
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
[TBL] [Abstract][Full Text] [Related]
8. Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
Kothari S; Hillengass J; McCarthy PL; Holstein SA
Curr Hematol Malig Rep; 2019 Feb; 14(1):39-46. PubMed ID: 30671912
[TBL] [Abstract][Full Text] [Related]
9. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
[TBL] [Abstract][Full Text] [Related]
10. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
Martinez-Lopez J; Alonso R; Wong SW; Rios R; Shah N; Ruiz-Heredia Y; Sanchez-Pina JM; Sanchez R; Bahri N; Zamanillo I; Poza M; Buenache N; Encinas C; Juarez L; Miras F; Collado L; Barrio S; Martin T; Cedena MT; Wolf J
J Hematol Oncol; 2021 Aug; 14(1):126. PubMed ID: 34404440
[TBL] [Abstract][Full Text] [Related]
11. MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment.
Landgren O; Lu SX; Hultcrantz M
Semin Hematol; 2018 Jan; 55(1):44-50. PubMed ID: 29759154
[TBL] [Abstract][Full Text] [Related]
12. Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?
Paiva B; Puig N; García-Sanz R; San Miguel JF;
Clin Cancer Res; 2015 May; 21(9):2001-8. PubMed ID: 25754350
[TBL] [Abstract][Full Text] [Related]
13. Multiple Myeloma Minimal Residual Disease.
Paiva B; García-Sanz R; San Miguel JF
Cancer Treat Res; 2016; 169():103-122. PubMed ID: 27696260
[TBL] [Abstract][Full Text] [Related]
14. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.
Landgren O; Devlin S; Boulad M; Mailankody S
Bone Marrow Transplant; 2016 Dec; 51(12):1565-1568. PubMed ID: 27595280
[TBL] [Abstract][Full Text] [Related]
15. Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.
Jamet B; Zamagni E; Nanni C; Bailly C; Carlier T; Touzeau C; Michaud AV; Moreau P; Bodet-Milin C; Kraeber-Bodere F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751375
[TBL] [Abstract][Full Text] [Related]
16. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
[TBL] [Abstract][Full Text] [Related]
17. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
[TBL] [Abstract][Full Text] [Related]
18. [Impact of minimal residual disease detection after treatment of multiple myeloma].
Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition.
Pianko MJ; Devlin SM; Littmann ER; Chansakul A; Mastey D; Salcedo M; Fontana E; Ling L; Tavitian E; Slingerland JB; Slingerland AE; Clurman A; Gomes ALC; Taur Y; Pamer EG; Peled JU; van den Brink MRM; Landgren O; Lesokhin AM
Blood Adv; 2019 Jul; 3(13):2040-2044. PubMed ID: 31289031
[TBL] [Abstract][Full Text] [Related]
20. Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.
Bal S; Costa LJ
Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 1(1):1-20. PubMed ID: 33843859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]